Amarin Corp. PLC (NASDAQ:AMRN) rose 0.7% during trading on Wednesday . The stock traded as high as $2.89 and last traded at $2.81, with a volume of 2,853,181 shares trading hands. The stock had previously closed at $2.79.

AMRN has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Amarin Corp. PLC in a research note on Monday, May 9th. Jefferies Group initiated coverage on Amarin Corp. PLC in a research note on Thursday, May 12th. They issued a “buy” rating and a $3.50 target price for the company. Finally, Zacks Investment Research cut Amarin Corp. PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, May 17th.

The company’s market capitalization is $524.12 million. The company has a 50 day moving average price of $2.86 and a 200 day moving average price of $2.06.

Amarin Corp. PLC (NASDAQ:AMRN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. During the same quarter in the previous year, the company posted ($0.15) earnings per share. The firm earned $32.82 million during the quarter, compared to the consensus estimate of $29.97 million. The firm’s revenue was up 85.4% on a year-over-year basis. Equities analysts anticipate that Amarin Corp. PLC will post ($0.46) EPS for the current year.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.